Free Stock Research Report: Allegion PLC (ALLE)

Many hedge fund managers, including Barry Rosenstein of Jana Partners, Nelson Peltz of Trian Partners, David E. Shaw of D E Shaw, Eric Mindich of Eton Park Capital and Steven Cohen of SAC Capital Advisors, reported new stakes in Allegion PLC (NYSE:ALLE) during fourth quarter of 2013.

Barry Rosenstein JANA PARTNERS

Beating the market can be difficult when picking stocks on your own. One common source of alpha can be focusing on small cap stocks, which tend to outperform its larger peers over time. Another source of alpha can be following the smart money, by mimicking the trades of professional investors. Our research has shown that, by combining these two approaches – buying the most popular small-cap stocks recently purchased by hedge funds – one can outperform the market on average (read the details here).

Most, if not all, of the hedge funds that own Allegion PLC (NYSE:ALLE) received their stakes due to their ownership of diversified industrial company Ingersoll-Rand PLC (NYSE: IR). Following pressure from activist investor Nelson Peltz, IR spun-off its residential and commercial security business to shareholders in a tax-free transaction in late November 2013, resulting in a Dublin-based publicly traded company called Allegion.

With annual revenue of $2 billion, annual EBITDA of $400 million and a market capitalization of $5.2 billion, ALLE is a leading provider of global provider of security solutions for homes and businesses. Operating in a $25 billion global market that is growing 5-7% but is highly fragmented, the company plans to expand both organically as well as through acquisitions. Allegion PLC (NYSE:ALLE) boasts above-average margin and return on invested capital metrics as well as strong free cash flow generation, which it will use for reinvestment in the business, opportunistic acquisitions and capital return through dividends (10-20% payout ratio) and share repurchases (to offset dilution). During its 4Q13 earnings release, ALLE provided EPS guidance of $2.25-2.40 for 2014, which compared favorably versus the consensus estimate of $2.27.

Spin-off situations tend to be good investment opportunities, as smaller divisions of larger companies tend to be misunderstood and incorrectly valued initially. In addition, the divested company can better focus on its specific business, increasing returns for shareholders in the process. Initially, however, the spun-off stock could underperform, as investors who received the shares might not want to hold it; once this initial selling pressure is gone, the stock tends to outperform. This seems to have been the case with Allegion PLC (NYSE:ALLE), whose stock declined 16.1% over 18 days since its spin-off on November 18, 2013 versus a 1.9% return for the S&P 500. Since then, however, the stock has appreciated 34.2% versus a 7.0% return for the overall market. Currently, the stock trades at a modest premium valuation to peers on a forward P/E basis (22.8X versus 21.9X for peers). We believe this premium is justified (and perhaps too small), as the denominator (earnings) should benefit from Allegion PLC (NYSE:ALLE)’s exposure to a recovering U.S. economy, as well as opportunities to grow in international markets (which comprise approximately a third of revenue) and expand margins in Europe and Asia-Pacific. With low requirements for working capital investments and capital expenditures, the company should be able to convert more of its EBITDA to free cash flow and, potentially, increase its payout to shareholders over time. Given these fundamental drivers, and as the market gains a better understanding of ALLE as a stand-alone business, we expect the stock to continue its outperformance.

Disclosure: none

Recommended Reading:

Brian Sheehy and Iszo Capital’s Top Stock Picks

Free Stock Research Report: AerCap Holdings NV (AER)

Free Stock Research Report: URS Corp

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!